Skip to content

Evaluation of the efficacy and safety of absorbable hemostatic gauze combined with topical tranexamic acid in reducing perioperative blood loss in total knee arthroplasty

Evaluation of the efficacy and safety of absorbable hemostatic gauze combined with topical tranexamic acid in reducing perioperative blood loss in total knee arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071664
Enrollment
Unknown
Registered
2023-05-22
Start date
2023-05-22
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee arthritis and total knee arthroplasty

Interventions

AH group:THA is performed using a standard anterior median incision and a medial parapatellar approach. A tourniquet is applied for 10 minutes at the time of skin incision and during cementation. Afte
TXA group:THA is performed using a standard anterior median incision and a medial parapatellar approach. A tourniquet is applied for 10 minutes at the time of skin incision and during cementation. Aft
AH + TXA group:THA is performed using a standard anterior median incision and a medial parapatellar approach. A tourniquet was applied for 10 minutes at the time of skin incision and during cementatio

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18~80 years; 2. American Society of Anesthesiologists (ASA) functional status of I-III; 3. Underwent TKA for primary end-stage knee osteoarthritis; 4. Consented to participate in the trial.

Exclusion criteria

Exclusion criteria: 1. Diagnoses other than primary osteoarthritis or preoperative anemia; 2. Allergic to tranexamic acid (TXA) or related drugs; 3. Anticoagulant use 7-14 days prior to surgery; 4. History of hematological disorders, venous thrombosis, or BMI>35 kg/m^2.

Design outcomes

Primary

MeasureTime frame
Total blood loss;Intraoperative blood loss;Hidden blood loss;Hemoglobin level;Hematocrit level;Maximum hemoglobin change;Number and volume of blood transfusion;Incidence rate of thrombosis;Wound-related complications;IV fluid amount;Number of anemia;Incidence of severe adverse events;

Secondary

MeasureTime frame
Platelet count;Activated partial thromboplastin time;Prothrombin time;Erythrocyte sedimentation rate;C-reactive protein;Interleukin-6 level;D-dimer level;Fibrinogen levels;Knee circumference;Knee mobility;HSS scores;VAS;Stride speed;Live and kidney functions (blood biochemistry);Incidence of other adverse reactions;

Countries

China

Contacts

Public ContactYi Zeng

West China Hospital, Sichuan University

zengyigd@126.com+86 189 8060 2289

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026